China Cardiovascular System Chemical Drugs Market Supply and Demand Analysis and Investment Profit Forecast Report 2023-2030

China Cardiovascular System Chemical Drugs Market Supply and Demand Analysis and Investment Profit Forecast Report 2023-2030

[Publisher]: Zhongying Xinhe Research Network

[The content part has been deleted, and the details can be found in the full information published by Zhongying Xinhe Research Network!]

Chapter 1: Overview of the Cardiovascular Systemic Chemical Drugs Industry and Data Sources

1.1 Definition and classification of cardiovascular diseases

1.1.1 Definition of cardiovascular disease

1.1.2 Classification of cardiovascular diseases

1.1.3 Characteristics of cardiovascular disease

1.2 Prevalence of cardiovascular disease in China

1.2.1 Risk factors for cardiovascular disease

1.2.2 Morbidity and mortality from cardiovascular diseases

(1) Number of patients

(2) Circumstances of death

1.2.3 Medical conditions of cardiovascular diseases

(1) Number of discharged

(2) Hospitalization expenses

1.3 Definition of cardiovascular system chemical drug industry

1.3.1 Definition of Cardiovascular Systemic Chemicals

1.3.2 Classification of cardiovascular systemic chemical drugs

1.3.3 Cardiovascular system chemical drug industry in the "National Economic Industry Classification and Code".

1.4 Explanation of professional terms in the cardiovascular system chemical drug industry

1.5 Scoping note for this report

1.6 Description of data sources and statistical standards in this report

Chapter 2: Macro Environment Analysis (PEST) of China's Cardiovascular Systemic Chemicals Industry

2.1 Policy environment analysis of China's cardiovascular system chemical drug industry

2.1.1 Introduction to the regulatory system and institutions of China's cardiovascular systemic chemical drug industry

(1) China's competent authority for cardiovascular system chemical drug industry

(2) Self-regulatory organization of China's cardiovascular system chemical drug industry

2.1.2 The status quo of the construction of the industry standard system for cardiovascular systemic chemical drugs in China

(1) Construction of standard system of chemical drugs in cardiovascular system in China

(2) Summary of the current standards for cardiovascular systemic chemical drugs in China

(3) China's cardiovascular system chemical drugs are about to implement standards

(4) Interpretation of key standards for cardiovascular system chemical drugs in China

2.1.3 Summary and interpretation of policies and plans related to the development of China's cardiovascular system chemical drug industry

(1) Summary of policies related to the development of China's cardiovascular system chemical drug industry

(2) Summary of relevant plans for the development of China's cardiovascular system chemical drug industry

2.1.4 Analysis of the impact of the national "14th Five-Year Plan" on the development of the cardiovascular systemic chemical drug industry

2.1.5 Summary of the impact of the policy environment on the development of China's cardiovascular systemic chemical drug industry

2.2 Analysis of the economic environment of China's cardiovascular system chemical drug industry

2.2.1 Current status of China's macroeconomic development

2.2.2 Macroeconomic outlook for China

2.2.3 Analysis of the correlation between the development and macroeconomic of China's cardiovascular systemic chemical drug industry

2.3 Analysis of the social environment of China's cardiovascular system chemical drug industry

2.3.1 Analysis of the social environment of China's cardiovascular systemic chemical drug industry

2.3.2 Summary of the impact of social environment on the cardiovascular system chemical drug industry

2.4 Technology environment analysis of China's cardiovascular system chemical drug industry

2.4.1 Technical processes and processes of China's cardiovascular system chemical drug industry

2.4.2 Analysis of key technologies in China's cardiovascular system chemical drug industry

2.4.3 R&D investment and innovation status of China's cardiovascular system chemical drug industry

2.4.4 Patent applications and disclosures in China's cardiovascular system chemical drug industry

(1) Patent application for cardiovascular system chemical drugs in China

(2) Patent disclosure of cardiovascular systemic chemical drugs in China

(3) Popular applicants for cardiovascular system chemical drugs in China

(4) Popular technologies for cardiovascular system chemical drugs in China

2.4.5 Summary of the impact of the technical environment on the development of China's cardiovascular system chemical drug industry

Chapter 3: Analysis of the development status and trend prospects of the global cardiovascular systemic chemical drug industry

3.1 Global prevalence of cardiovascular disease

3.2 Macro environment background of the global cardiovascular system chemical drug industry

3.2.1 Overview of the economic environment of the global cardiovascular system chemical drug industry

3.2.2 Overview of the political and legal environment of the global cardiovascular system chemical drug industry

3.2.3 Overview of the technical environment of the global cardiovascular system chemical drug industry

3.2.4 Analysis of the impact of the new crown epidemic on the global cardiovascular system chemical drug industry

3.3 Analysis of the development status and market size of the global cardiovascular system chemical drug industry

3.3.1 Overview of the development status of the global cardiovascular systemic chemical drug industry

3.3.2 Global Cardiovascular Systemic Chemical Drugs Industry Market Size

3.3.3 Global Cardiovascular Systemic Chemicals Industry Segment Analysis

3.4 Regional development pattern and key regional market research of the global cardiovascular system chemical drug industry

3.4.1 Regional development pattern of the global cardiovascular system chemical drug industry

3.4.2 Market development in key regions of the global cardiovascular system chemical drug industry

(1) Analysis of the development status of the cardiovascular system chemical drug industry in the United States

(2) Analysis of the development status of the European cardiovascular system chemical drug industry

(3) Analysis of the development status of the cardiovascular system chemical drug industry in Japan

3.5 Global Cardiovascular Systemic Chemicals Industry Market Competition Pattern and Key Company Case Studies

3.5.1 Global Cardiovascular Systemic Chemicals Industry Market Competitive Landscape

3.5.2 Global Mergers and Acquisitions of Cardiovascular Systemic Chemical Companies

3.5.3 Cases of key enterprises in the global cardiovascular system chemical drug industry (customizable)

（1）拜耳（Bayer AG）

(2)赛诺菲(Sanofi)

(3)百时美施贵宝(Bristol-Myers Squibb)

（4）强生（Johnson & Johnson）

（5）辉瑞（Pfizer Inc）

(6)诺华(Novartis)

3.6 Prediction of the development trend and market prospect of the global cardiovascular system chemical drug industry

3.6.1 Prediction of the development trend of the global cardiovascular system chemical drug industry

3.6.2 Global Cardiovascular Systemic Chemicals Industry Market Prospect Forecast

3.7 Lessons from the development experience of the global cardiovascular system chemical drug industry

Chapter 4: Analysis of the development status of China's cardiovascular systemic chemical drug industry

4.1 Overview of the development of China's cardiovascular system chemical drug industry

4.2 Supply analysis of China's cardiovascular system chemical drug industry

4.2.1 Types of market players and entry methods in China's cardiovascular system chemical drug industry

4.2.2 The number and scale of market players in China's cardiovascular system chemical drug industry

4.2.3 Current status of product R&D (supply) in China's cardiovascular system chemical drug industry

4.3 Demand analysis of China's cardiovascular system chemical drug industry

4.3.1 Sales scale of cardiovascular system chemicals in China

4.3.2 Sales scale of cardiovascular systemic chemical drugs in China through different channels

(1) Hospital channels

(2) Retail channels

4.3.3 Sales scale of cardiovascular systemic chemical drugs by type in China

(1) Sales by subcategory

(2) Sales by dosage form

Chapter 5: Market Competition and International Market Competitiveness Analysis of China's Cardiovascular Systemic Chemicals Industry

5.1 Analysis of Porter's Five Forces Model in China's Cardiovascular Systemic Chemical Drug Industry

5.1.1 Competitive analysis among existing competitors in China's cardiovascular system chemical drug industry

5.1.2 Analysis of supplier bargaining power of key elements of China's cardiovascular system chemical drug industry

5.1.3 Analysis of consumer bargaining power in China's cardiovascular system chemical drug industry

5.1.4 Analysis of potential entrants in China's cardiovascular system chemical drug industry

5.1.5 Risk analysis of alternatives in China's cardiovascular system chemical drug industry

5.1.6 Summary of competition in China's cardiovascular system chemical drug industry

5.2 Investment, financing, mergers and acquisitions in China's cardiovascular system chemical drug industry

5.2.1 Investment and financing development of China's cardiovascular system chemical drug industry

(1) Funding sources for China's cardiovascular system chemical drug industry

(2) The main investment and financing entity of China's cardiovascular system chemical drug industry

(3) Investment and financing methods of China's cardiovascular system chemical drug industry

(4) Summary of investment and financing events in China's cardiovascular system chemical drug industry

(5) Summary of investment and financing information of China's cardiovascular system chemical drug industry

(6) Forecast of investment and financing trends in China's cardiovascular system chemical drug industry

5.2.2 Mergers and acquisitions of China's cardiovascular system chemical drug industry

(1) Summary of mergers and acquisitions in China's cardiovascular system chemical drug industry

(2) Analysis of the drivers of mergers and acquisitions in China's cardiovascular system chemical drug industry

(3) Case study of mergers and acquisitions in China's cardiovascular system chemical drug industry

(4) Prediction of the trend of mergers and acquisitions in China's cardiovascular system chemical drug industry

5.3 Analysis of the market competition pattern of China's cardiovascular system chemical drug industry

5.3.1 Competitive landscape of enterprises in China's cardiovascular system chemical drug industry

5.3.2 Product Competitive Landscape of China's Cardiovascular Systemic Chemical Drugs Industry

5.4 Analysis of market concentration of China's cardiovascular system chemical drug industry

5.5 Analysis of the international market competitiveness of China's cardiovascular system chemical drug industry

5.6 Overseas layout of key enterprises in China's cardiovascular system chemical drug industry

Chapter 6: China Cardiovascular Systemic Chemicals Industry Segmentation by Subclass Market Analysis

6.1 Cardiovascular System Chemicals Industry Segmentation by Subcategory Market Overview

6.1.1 Major sub-categories of cardiovascular system chemical drugs

6.1.2 Cardiovascular Systemic Chemicals Industry Segmentation by Subcategory Market Landscape

6.2 β-Blockers Market Analysis

6.2.1 Overview of β-Blocker Products

6.2.2 β-Blocker Market Overview

6.2.3 β-Blockers Market Size

6.2.4 Analysis of the main products of β-receptor blockers

6.2.5 β-Blocker Competitive Landscape

6.2.6 β-Blocker Market Prospects and Trends

6.3 Calcium channel blocker market analysis

6.3.1 Overview of calcium channel blocker products

6.3.2 Calcium channel blockers market overview

6.3.3 Calcium channel blockers market size

6.3.4 Analysis of the main products of calcium channel blockers

6.3.5 Calcium channel blocker competitive landscape

6.3.6 Calcium channel blockers market outlook and trends

6.4 Diuretics Market Analysis

6.4.1 Overview of diuretic products

6.4.2 Diuretics Market Overview

6.4.3 Diuretics Market Size

6.4.4 Analysis of main diuretic products

6.4.5 Diuretics Competitive Landscape

6.4.6 Diuretics Market Prospects and Trends

6.5 Cardiac Treatment Drugs Market Analysis

6.5.1 Overview of Cardiac Treatment Medications

6.5.2 Overview of the Cardiac Treatment Drugs Market

6.5.3 Cardiac Treatment Drugs Market Size

6.5.4 Analysis of main products for the treatment of heart disease

6.5.5 Competitive landscape of cardiac treatment drugs

6.5.6 Prospects and trends of the market for the treatment of heart disease

6.6 Vasoprotectants Market Analysis

6.6.1 Overview of vasoprotectant products

6.6.2 Overview of the vasoprotective agents market

6.6.3 Vascular Protectors Market Size

6.6.4 Analysis of main products of vascular protectors

6.6.5 Competitive landscape of vasoprotectants

6.6.6 Vasoprotectants Market Prospects and Trends

6.7 Lipid Modulators Market Analysis

6.7.1 Overview of lipid modulator products

6.7.2 Overview of the lipid modulator market

6.7.3 Blood lipid modulators market size

6.7.4 Analysis of the main products of blood lipid modulators

6.7.5 Competitive landscape of lipid modulators

6.7.6 Lipid Regulators Market Prospects and Trends

6.8 Peripheral Vasodilator Market Analysis

6.8.1 Overview of peripheral vasodilator products

6.8.2 Overview of the peripheral vasodilator market

6.8.3 Peripheral Vasodilators Market Size

6.8.4 Analysis of major products of peripheral vasodilators

6.8.5 Competitive landscape of peripheral vasodilators

6.8.6 Peripheral vasodilator market outlook and trends

6.9 Dedicated to antihypertensive drug market analysis

6.9.1 Overview of products dedicated to antihypertensive drugs

6.9.2 Market overview dedicated to antihypertensive drugs

6.9.3 Market size dedicated to antihypertensive drugs

6.9.4 Dedicated to the analysis of the main products of antihypertensive drugs

6.9.5 Dedicated to the competitive landscape of antihypertensive drugs

6.9.6 Market prospects and trends dedicated to antihypertensive drugs

6.10 Market Analysis for Drugs Acting on the Renin-Angiotensin System

6.10.1 Overview of drug products acting on the renin-angiotensin system

6.10.2 Overview of the renin-angiotensin system drugs market

6.10.3 Market Size of Drugs Acting on Renin-Angiotensin System

6.10.4 Analysis of the main products of drugs acting on the renin-angiotensin system

6.10.5 Competitive landscape of drugs acting on the renin-angiotensin system

6.10.6 Market Prospects and Trends of Drugs Acting on the Renin-Angiotensin System

Chapter 7: China Cardiovascular Systemic Chemicals Industry Segmentation by Product Name

7.1 Segmentation of China's Cardiovascular Systemic Chemical Drugs Industry by Product Name

7.2 Butaphthalide Market Analysis

7.2.1 Overview of butylphthalide products

7.2.2 Sales scale of butylphthalide

7.2.3 Main manufacturers and patterns of butadiphthalein

7.3 Atorvastatin Market Analysis

7.3.1 Atorvastatin Product Overview

7.3.2 Atorvastatin sales scale

7.3.3 Major manufacturers and patterns of atorvastatin

7.4 Nifedipine Market Analysis

7.4.1 Nifedipine Product Overview

7.4.2 Nifedipine sales scale

7.4.3 Major manufacturers and patterns of nifedipine

7.5 Valsartan Market Analysis

7.5.1 Overview of valsartan products

7.5.2 Valsartan sales scale

7.5.3 Main manufacturers and pattern of valsartan

7.6 Levoamlodipine (Levamlodipine) Market Analysis

7.6.1 Overview of levamlodipine (levamlodipine) products

7.6.2 Sales scale of levamlodipine (levamlodipine).

7.6.3 Major manufacturers and patterns of levamlodipine (levamlodipine).

7.7 Rosuvastatin Market Analysis

7.7.1 Rosuvastatin Product Overview

7.7.2 Rosuvastatin sales scale

7.7.3 Major manufacturers and patterns of rosuvastatin

7.8 Isosorbide mononitrate market analysis

7.8.1 Overview of isosorbide mononitrate products

7.8.2 Sales scale of isosorbide mononitrate

7.8.3 Major manufacturers and patterns of isosorbide mononitrate

7.9 Valsartan Amlodipine Market Analysis

7.9.1 Overview of Valsartan Amolodi

7.9.2 Sales scale of valsartan aminochloride

7.9.3 Main manufacturers and pattern of valsartan aminochloride

7.10 Metoprolol Market Analysis

7.10.1 Overview of Torol Products

7.10.2 Tolor sales scale

7.10.3 Torrol's main production enterprises and patterns

Chapter 8: Panoramic review of China's cardiovascular system chemical drug industry chain and supply chain layout diagnosis

8.1 Analysis of the industrial structure attributes (industrial chain) of China's cardiovascular system chemical drugs

8.1.1 Sorting out the structure of China's cardiovascular systemic chemical drug industry chain

8.1.2 Ecological map of China's cardiovascular system chemical drug industry chain

8.2 Analysis of the value attributes (value chain) of China's cardiovascular systemic chemical drug industry

8.2.1 Cost structure analysis of China's cardiovascular system chemical drug industry

8.2.2 Value chain analysis of China's cardiovascular systemic chemical drug industry

8.3 Analysis of the upstream supply market of China's cardiovascular system chemical drug industry

8.3.1 Overview of the upstream market of China's cardiovascular system chemical drug industry

8.3.2 Analysis of the upstream price transmission mechanism of China's cardiovascular systemic chemical drug industry

8.3.3 Summary of the impact of the upstream supply market of China's cardiovascular system chemical drug industry

8.4 Analysis of the main API in the upstream of the cardiovascular system chemical drug industry - puli

8.4.1 Overview of proli-based APIs

8.4.2 Supply of proli-based APIs

8.4.3 Competitive landscape of pull APIs

8.4.4 Price trend of pulp APIs

8.4.5 Summary of the impact of the supply of puli APIs on the cardiovascular system chemical drug industry

8.5 Analysis of the market of the main upstream APIs in the cardiovascular system chemical drug industry - sartans

8.5.1 Overview of sartan APIs

8.5.2 Supply of sartan APIs

8.5.3 Competitive landscape of sartan APIs

8.5.4 Price trend of sartan APIs

8.5.5 Summary of the impact of sartan API supply on the cardiovascular systemic chemical drug industry

8.6 Analysis of the statin market of the main APIs in the upstream of the cardiovascular system chemical drug industry

8.6.1 Overview of statin APIs

8.6.2 Supply of statin APIs

8.6.3 Statin API Competitive Landscape

8.6.4 Price trend of statin APIs

8.6.5 Summary of the impact of statin API supply on the cardiovascular systemic chemical industry

8.7 Downstream market analysis of cardiovascular system chemical drug industry

8.7.1 Market analysis of hospital-end cardiovascular systemic chemical drugs

(1) Hospital-end cardiovascular systemic chemical drug procurement model

(2) The market size of hospital-end cardiovascular system chemical drugs

(3) TOP products of cardiovascular system chemical drugs at the hospital end

(4) The competitive landscape of cardiovascular systemic chemical drugs at the hospital end

8.7.2 Retail Cardiovascular Systemic Chemicals Market Analysis

(1) Channel analysis of cardiovascular systemic chemical drugs at the retail end

(2) The market size of cardiovascular system chemical drugs at the retail end

(3) TOP products of cardiovascular system chemical drugs at the retail end

(4) The competitive landscape of cardiovascular systemic chemical drugs at the retail end

8.8 Diagnosis of the supply chain layout of China's cardiovascular system chemical drug industry

Chapter 9: China Cardiovascular Systemic Chemicals Key Regional Market Analysis

9.1 Regional development of China's cardiovascular system chemical drug industry

9.1.1 Analysis of cardiovascular health index of provinces and cities in China

9.1.2 Regional development of China's cardiovascular system chemical drug industry

9.2 Analysis of the Beijing Cardiovascular Systemic Chemical Drugs Market

9.2.1 Analysis of the development environment of the cardiovascular system chemical drug industry in Beijing

9.2.2 Analysis of the scale of the cardiovascular system chemical drug industry in Beijing

9.2.3 Competitive analysis of cardiovascular system chemical drug industry in Beijing

9.2.4 Analysis of major players in the cardiovascular system chemical drug industry in Beijing

9.2.5 Trend and prospect analysis of cardiovascular system chemical drug industry in Beijing

9.3 Analysis of the cardiovascular system chemical drugs market in Shanghai

9.3.1 Analysis of the development environment of the cardiovascular system chemical drug industry in Shanghai

9.3.2 Analysis of the scale of the cardiovascular system chemical drug industry in Shanghai

9.3.3 Competitive analysis of cardiovascular system chemical drug industry in Shanghai

9.3.4 Analysis of major players in the cardiovascular system chemical drug industry in Shanghai

9.3.5 Trends and prospects of cardiovascular systemic chemical drugs in Shanghai

9.4 Analysis of the cardiovascular system chemical drugs market in Guangdong Province

9.4.1 Analysis of the development environment of the cardiovascular system chemical drug industry in Guangdong Province

9.4.2 Cardiovascular Systemic Chemical Drugs Industry Scale Analysis in Guangdong Province

9.4.3 Competitive analysis of cardiovascular system chemical drug industry in Guangdong Province

9.4.4 Analysis of major players in the cardiovascular system chemical drug industry in Guangdong Province

9.4.5 Trend and prospect analysis of cardiovascular system chemical drug industry in Guangdong Province

9.5 Analysis of the cardiovascular system chemical drugs market in Jiangsu Province

9.5.1 Analysis of the development environment of the cardiovascular system chemical drug industry in Jiangsu Province

9.5.2 Analysis of the scale of the cardiovascular system chemical drug industry in Jiangsu Province

9.5.3 Competitive analysis of cardiovascular system chemical drug industry in Jiangsu Province

9.5.4 Analysis of major players in the cardiovascular system chemical drug industry in Jiangsu Province

9.5.5 Trend and prospect analysis of cardiovascular system chemical drug industry in Jiangsu Province

9.6 Zhejiang Province Cardiovascular Systemic Chemical Drugs Market Analysis

9.6.1 Analysis of the development environment of the cardiovascular systemic chemical drug industry in Zhejiang Province

9.6.2 Cardiovascular system chemical drug industry scale analysis in Zhejiang Province

9.6.3 Competitive analysis of cardiovascular system chemical drug industry in Zhejiang Province

9.6.4 Analysis of major players in the cardiovascular system chemical drug industry in Zhejiang Province

9.6.5 Trend and prospect analysis of cardiovascular system chemical drug industry in Zhejiang Province

Chapter 10: Tracking the development pain points of China's cardiovascular systemic chemical drug industry and the trend of industrial transformation and upgrading

10.1 Business Model Analysis of China's Cardiovascular Systemic Chemicals Industry

10.2 Analysis of the operating benefits of China's cardiovascular systemic chemical drug industry

10.2.1 Revenue of China's cardiovascular system chemical drug industry

10.2.2 Profit level of China's cardiovascular system chemical drug industry

10.2.3 Cost control of China's cardiovascular system chemical drug industry

10.3 Analysis of the market pain points of China's cardiovascular system chemical drug industry

10.4 The development path of China's cardiovascular system chemical industry structure optimization, transformation and upgrading

10.5 Tracking of the Trend of Industrial Optimization, Transformation and Upgrading of China's Cardiovascular System Chemical Drug Industry

10.5.1 Tracking of the Trend of Structural Optimization and Layout of China's Cardiovascular System Chemical Industry Industry

10.5.2 Tracking of the information management layout of China's cardiovascular system chemical drug industry

10.5.3 Tracking the trend of digital transformation of China's cardiovascular system chemical drug industry

10.5.4 Tracking of the low-carbon/green transformation layout of China's cardiovascular system chemical drug industry

Chapter 11: Case Study of China's Cardiovascular Systemic Chemical Firm Layout

11.1 Layout of China's cardiovascular system chemical drug companies

11.2 Case Study of the Layout of Cardiovascular Systemic Chemical Drugs in China (in no particular order; customizable)

11.2.1 CSPC Pharmaceutical Group Enbipu Pharmaceutical Co., Ltd

(1) Enterprise development history and basic information

(2) The basic situation of the production and operation of the enterprise

(3) The company's cardiovascular system chemical drug business layout and product/service details

(4) The upstream and downstream extension layout of the cardiovascular system chemical drug industry chain of the enterprise

(5) Business layout planning and latest trend tracking of cardiovascular system chemical drugs of the enterprise

(6) Analysis of the advantages and disadvantages of the company's cardiovascular system chemical drug business layout

11.2.2 Qilu Pharmaceutical Group Co., Ltd

(1) Enterprise development history and basic information

(2) The basic situation of the production and operation of the enterprise

(3) The company's cardiovascular system chemical drug business layout and product/service details

(4) The upstream and downstream extension layout of the cardiovascular system chemical drug industry chain of the enterprise

(5) Business layout planning and latest trend tracking of cardiovascular system chemical drugs of the enterprise

(6) Analysis of the advantages and disadvantages of the layout of cardiovascular systemic chemical drugs in enterprises

11.2.3 Tibet Nordic Pharmaceutical Co., Ltd

(1) Enterprise development history and basic information

(2) The basic situation of the production and operation of the enterprise

(3) The company's cardiovascular system chemical drug business layout and product/service details

(4) The upstream and downstream extension layout of the cardiovascular system chemical drug industry chain of the enterprise

(5) Business layout planning and latest trend tracking of cardiovascular system chemical drugs of the enterprise

(6) Analysis of the advantages and disadvantages of the layout of cardiovascular systemic chemical drugs in enterprises

11.2.4 Sihuan Pharmaceutical Holdings Group Co., Ltd

(1) Enterprise development history and basic information

(2) The basic situation of the production and operation of the enterprise

(3) The company's cardiovascular system chemical drug business layout and product/service details

(4) The upstream and downstream extension layout of the cardiovascular system chemical drug industry chain of the enterprise

(5) Business layout planning and latest trend tracking of cardiovascular system chemical drugs of the enterprise

(6) Analysis of the advantages and disadvantages of the layout of cardiovascular systemic chemical drugs in enterprises

11.2.5 China Resources Shuanghe Pharmaceutical Co., Ltd

(1) Enterprise development history and basic information

(2) The basic situation of the production and operation of the enterprise

(3) The company's cardiovascular system chemical drug business layout and product/service details

(4) The upstream and downstream extension layout of the cardiovascular system chemical drug industry chain of the enterprise

(5) Business layout planning and latest trend tracking of cardiovascular system chemical drugs of the enterprise

(6) Analysis of the advantages and disadvantages of the layout of cardiovascular systemic chemical drugs in enterprises

11.2.6 Beijing Shuanglu Pharmaceutical Co., Ltd

(1) Enterprise development history and basic information

(2) The basic situation of the production and operation of the enterprise

(3) The company's cardiovascular system chemical drug business layout and product/service details

(4) The upstream and downstream extension layout of the cardiovascular system chemical drug industry chain of the enterprise

(5) Business layout planning and latest trend tracking of cardiovascular system chemical drugs of the enterprise

(6) Analysis of the advantages and disadvantages of the layout of cardiovascular systemic chemical drugs in enterprises

11.2.7 Lunan Pharmaceutical Group Co., Ltd

(1) Enterprise development history and basic information

(2) The basic situation of the production and operation of the enterprise

(3) The company's cardiovascular system chemical drug business layout and product/service details

(4) The upstream and downstream extension layout of the cardiovascular system chemical drug industry chain of the enterprise

(5) Business layout planning and latest trend tracking of cardiovascular system chemical drugs of the enterprise

(6) Analysis of the advantages and disadvantages of the layout of cardiovascular systemic chemical drugs in enterprises

11.2.8 CSPC Ouyi Pharmaceutical Co., Ltd

(1) Enterprise development history and basic information

(2) The basic situation of the production and operation of the enterprise

(3) The company's cardiovascular system chemical drug business layout and product/service details

(4) The upstream and downstream extension layout of the cardiovascular system chemical drug industry chain of the enterprise

(5) Business layout planning and latest trend tracking of cardiovascular system chemical drugs of the enterprise

(6) Analysis of the advantages and disadvantages of the layout of cardiovascular systemic chemical drugs in enterprises

11.2.9 Ruiyang Pharmaceutical Co., Ltd

(1) Enterprise development history and basic information

(2) The basic situation of the production and operation of the enterprise

(3) The company's cardiovascular system chemical drug business layout and product/service details

(4) The upstream and downstream extension layout of the cardiovascular system chemical drug industry chain of the enterprise

(5) Business layout planning and latest trend tracking of cardiovascular system chemical drugs of the enterprise

(6) Analysis of the advantages and disadvantages of the layout of cardiovascular systemic chemical drugs in enterprises

11.2.10 Beijing Tide Pharmaceutical Co., Ltd

(1) Enterprise development history and basic information

(2) The basic situation of the production and operation of the enterprise

(3) The company's cardiovascular system chemical drug business layout and product/service details

(4) The upstream and downstream extension layout of the cardiovascular system chemical drug industry chain of the enterprise

(5) Business layout planning and latest trend tracking of cardiovascular system chemical drugs of the enterprise

(6) Analysis of the advantages and disadvantages of the layout of cardiovascular systemic chemical drugs in enterprises

Chapter 12: Evaluation of the development potential and trend prospect of China's cardiovascular systemic chemical drug industry

12.1 SWOT analysis of China's cardiovascular systemic chemical drug industry

12.2 Evaluation of the development potential of China's cardiovascular system chemical drug industry

12.3 Market Prospect Forecast of China's Cardiovascular Systemic Chemical Drugs Industry

12.4 Prediction of the development trend of China's cardiovascular system chemical drug industry

Chapter 13: Analysis of Investment Value and Investment Opportunities in China's Cardiovascular Systemic Chemicals Industry

13.1 Analysis of market entry and exit barriers in China's cardiovascular systemic chemical drug industry

13.1.1 Talent barriers in the cardiovascular system chemical drug industry

13.1.2 Technical barriers in the cardiovascular system chemical drug industry

13.1.3 Financial barriers in the cardiovascular system chemical drug industry

13.1.4 Other barriers in the cardiovascular system chemical drug industry

13.2 Early warning and prevention of investment risks in China's cardiovascular system chemical drug industry

13.2.1 Policy risks and prevention of cardiovascular system chemical drug industry

13.2.2 Technical risks and prevention in the cardiovascular system chemical drug industry

13.2.3 Risks and prevention of macroeconomic fluctuations in the cardiovascular system chemical drug industry

13.2.4 Risks and prevention of related industries in the cardiovascular system chemical drug industry

13.2.5 Other risks and precautions in the cardiovascular system chemical drug industry

13.3 Evaluation of the investment value of China's cardiovascular system chemical drug industry

13.4 Analysis of Investment Opportunities in China's Cardiovascular Systemic Chemical Drugs Industry

13.4.1 Investment opportunities in the weak links of the industrial chain of the cardiovascular system chemical drug industry

13.4.2 Investment opportunities in the cardiovascular system chemical drug industry segments

13.4.3 Regional Market Investment Opportunities in the Cardiovascular Systemic Chemicals Industry

13.4.4 Blank investment opportunities in the cardiovascular system chemical drug industry

Chapter 14: Investment Strategies and Sustainable Development Recommendations for China's Cardiovascular Systemic Chemicals Industry

14.1 Investment Strategies and Suggestions for China's Cardiovascular Systemic Chemical Drugs Industry

14.2 Suggestions for the sustainable development of China's cardiovascular systemic chemical drug industry

Table of Contents of Charts

Figure 1: Definition of cardiovascular disease

Figure 2: Classification of cardiovascular diseases

Figure 3: Cardiovascular system chemical drug industry in the "National Economic Industry Classification and Code".

Figure 4: Explanation of professional terms in the cardiovascular system chemical drug industry

Figure 5: Scoping of the study

Figure 6: Data sources and statistical standards in this report

Figure 7: Regulatory system of China's cardiovascular systemic chemical drug industry

Exhibit 8: China's Cardiovascular Systemic Chemical Drugs Industry Authorities

Exhibit 9: Self-Regulatory Organizations in China's Cardiovascular Systemic Chemical Drug Industry

Figure 10: Construction of standard system for chemical drugs in cardiovascular system in China

Figure 11: Summary of current standards for cardiovascular systemic chemical drugs in China

Figure 12: Chinese cardiovascular systemic chemical drugs are about to be implemented

Figure 13: Interpretation of key standards for cardiovascular system chemical drugs in China

Figure 14: Summary of China's cardiovascular system chemical drug industry development policies as of 2023

Figure 15: Summary of the development plan of China's cardiovascular system chemical drug industry as of 2023

Figure 16: Analysis of the impact of the national "14th Five-Year Plan" on the development of the cardiovascular system chemical drug industry

Figure 17: Summary of the impact of the policy environment on the development of China's cardiovascular systemic chemical drug industry

Figure 18: Current status of China's macroeconomic development

Exhibit 19: China's macroeconomic outlook

Exhibit 20: Analysis of the correlation between the development of China's cardiovascular system chemical drug industry and the macroeconomy

Figure 21: Analysis of the social environment of China's cardiovascular systemic chemical drug industry

Exhibit 22: Summary of the impact of the social environment on the cardiovascular systemic chemicals industry

Figure 23: Technology and process of China's cardiovascular system chemical drug industry

Figure 24: Analysis of key technologies in China's cardiovascular system chemical drug industry

Figure 25: R&D investment and innovation status of China's cardiovascular systemic chemical drug industry

Figure 26: Patent applications for cardiovascular systemic chemical drugs in China

Exhibit 27: Patent disclosure of chemical drugs for cardiovascular systems in China

Exhibit 28: Top applicants for cardiovascular systemic chemical drugs in China

Figure 29: Popular technologies for cardiovascular systemic chemicals in China

Figure 30: Summary of the impact of the technology environment on the development of China's cardiovascular systemic chemical drug industry

Exhibit 31: Overview of the economic environment of the global cardiovascular system chemical industry

Exhibit 32: Overview of the political and legal environment of the global cardiovascular systemic chemical drug industry

Exhibit 33: Overview of the global technology environment for the cardiovascular system chemical industry

Exhibit 34: Analysis of the impact of the pandemic on the global cardiovascular system chemicals industry

Exhibit 35: Global Cardiovascular Systemic Chemicals Industry Market Size 2019-2023

Figure 36: Global development status of cardiovascular systemic chemical drug industry

Exhibit 37: Global Cardiovascular Systemic Chemicals Industry Market Size Analysis

Exhibit 38: Global Cardiovascular Systemic Chemicals Industry Segment Landscape

Figure 39: Regional development pattern of the global cardiovascular system chemical drug industry

Exhibit 40: Global Cardiovascular Systemic Chemicals Industry Market Analysis by Key Regions

Exhibit 41: Global Cardiovascular Systemic Chemicals Industry Market Competitive Landscape

Exhibit 42: Global mergers and acquisitions of cardiovascular systemic chemical companies

Exhibit 43: Bayer's operating income from 2019 to 2023 (unit: USD billion, %)

Exhibit 44: Bayer's main product mix by revenue, 2023 (unit: %)

Exhibit 45: Bayer AG market distribution by revenue, 2023 (unit: %)

Exhibit 46: Sanofi's operating income from 2019 to 2023 (unit: US$ 100 million, %)

Exhibit 47: Sanofi's Key Product Mix by Revenue, 2023 (Unit: %)

Exhibit 48: Sanofi market distribution by revenue, 2023 (in %)

Exhibit 49: Bristol-Myers Squibb operating revenue, 2019-2023 (unit: US$ billion, %)

Exhibit 50: Bristol-Myers Squibb's Key Product Mix by Revenue, 2023 (in %)

Exhibit 51: Bristol-Myers Squibb Company Market Distribution by Revenue, 2023 (Unit: %)

Figure 52: Johnson & Johnson's operating income from 2019 to 2023 (unit: US$ billion, %)

Exhibit 53: Johnson & Johnson's Key Product Mix by Revenue, 2023 (Unit: %)

Exhibit 54: Johnson & Johnson Market Distribution by Revenue, 2023 (Unit: %)

Exhibit 55: Pfizer's operating income from 2019 to 2023 (unit: US$ billion, %)

Exhibit 56: Pfizer's Key Product Mix by Revenue, 2023 (Unit: %)

Exhibit 57: Pfizer market distribution by revenue, 2023 (in %)

Exhibit 58: Novartis operating income from 2019 to 2023 (unit: US$ 100 million, %)

Exhibit 59: Novartis' Key Product Mix by Revenue, 2023 (Unit: %)

Exhibit 60: Novartis market distribution by revenue, 2023 (in %)

Figure 61: Forecast of the development trend of the global cardiovascular system chemical drug industry

Exhibit 62: Global Cardiovascular Systemic Chemicals Industry Market Outlook 2023-2030

Exhibit 63: Market size analysis of China's cardiovascular system chemical drug industry

Figure 64: Hospital scale of China's cardiovascular systemic chemical drug industry

Figure 65: Retail scale of China's cardiovascular system chemical industry

Exhibit 66: Competitive analysis of incumbents in China's cardiovascular system chemical industry

Exhibit 67: Analysis of upstream bargaining power of China's cardiovascular systemic chemical industry

Exhibit 68: Analysis of downstream bargaining power in China's cardiovascular system chemical industry

Exhibit 69: Threat analysis of potential entrants in China's cardiovascular systemic chemical industry

Exhibit 70: Risk analysis of potential alternatives to China's cardiovascular system chemical industry

Exhibit 71: Comprehensive analysis of the five forces competition in China's cardiovascular system chemical drug industry

Exhibit 72: Investment and financing development of China's cardiovascular system chemical drug industry

Exhibit 73: Mergers and acquisitions of China's cardiovascular systemic chemical drug industry

Exhibit 74: Competitive Landscape Analysis of China's Cardiovascular Systemic Chemicals Industry

Exhibit 75: Market concentration analysis of China's cardiovascular system chemical drug industry

Exhibit 76: Analysis of the international market competitiveness of China's cardiovascular systemic chemical drug industry

Exhibit 77: Overseas layout of key enterprises in China's cardiovascular system chemical drug industry

Exhibit 78: China Cardiovascular Systemic Chemicals Industry Segmentation by Subcategory Market Landscape

Exhibit 79: China β-Blockers Market Size

Figure 80: China's β-Blocker Competitive Landscape

Figure 81: China calcium channel blocker market size

Figure 82: Competitive landscape of calcium channel blockers in China

Exhibit 83: China Diuretics Market Size

Exhibit 84: Diuretics Competitive Landscape in China

Exhibit 85: Market size of drugs for the treatment of heart disease in China

Figure 86: Competitive landscape of cardiac treatment drugs in China

Exhibit 87: China vasoprotectants market size

Exhibit 88: Competitive landscape of vasoprotective agents in China

Figure 89: China lipid modulator market size

Figure 90: Competitive landscape of lipid modulators in China

Exhibit 91: China Peripheral Vasodilator Market Size

Exhibit 92: Competitive landscape of peripheral vasodilators in China

Exhibit 93: China market size dedicated to antihypertensive drugs

Exhibit 94: China's competitive landscape dedicated to antihypertensive drugs

Exhibit 95: China market size of drugs acting on the renin-angiotensin system

Exhibit 96: Competitive landscape of drugs acting on the renin-angiotensin system in China

Exhibit 97: China Cardiovascular Systemic Chemicals Industry Segmentation by Product Name

Figure 98: Sales scale of butylphthalide in China

Exhibit 99: Sales pattern of major butylphthalide companies in China

Figure 100: Atorvastatin sales in China

Exhibit 101: Sales pattern of atorvastatin by major companies in China

Exhibit 102: Sales volume of nifedipine in China

Exhibit 103: Sales pattern of major companies in China Nifedipine

Figure 104: Sales scale of valsartan in China

Exhibit 105: Sales pattern of major companies in China valsartan

Figure 106: Sales of levamlodipine (levamlodipine) in China

Exhibit 107: Sales pattern of major companies in China levamlodipine (levamlodipine).

Exhibit 108: Rosuvastatin sales in China

Exhibit 109: Sales pattern of rosuvastatin by major companies in China

Figure 110: Sales scale of isosorbide mononitrate in China

Exhibit 111: Sales pattern of major companies in China isosorbide mononitrate

Figure 112: Sales scale of valsartan aminochloride in China

Exhibit 113: Sales pattern of major companies in China valsartan aminochloride

Exhibit 114: Torol sales in China

Exhibit 115: Sales pattern of major companies in Torol, China

Figure 116: Structural analysis of China's cardiovascular systemic chemical drug industry chain

Figure 117: Ecological map of China's cardiovascular system chemical drug industry chain

Exhibit 118: Cost structure analysis of China's cardiovascular systemic chemical drug industry

Exhibit 119: Value chain analysis of China's cardiovascular systemic chemical industry

Exhibit 120: Overview of the upstream market of China's cardiovascular systemic chemical drug industry